BDX Unveils Portable PureWick System for On-the-Go Incontinence Care
BD expands its PureWick line with a portable system built for discreet, mobile incontinence care, aiming to deepen its home-care reach.
STXS Secures FDA Approval for GenesisX to Broaden Surgical Robotics
Stereotaxis wins FDA clearance for GenesisX, a streamlined robotic system aimed at boosting hospital adoption and accelerating growth.
SOLV vs. DHR: Which Stock Is the Better Value Option?
Investors interested in Medical Services stocks are likely familiar with Solventum ( SOLV Quick QuoteSOLV - ) and Danaher ( DHR Quick QuoteDHR - ) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
Here's Why You Should Hold DexCom Stock in Your Portfolio for Now
DXCM's strong Q3 growth, expanding CGM coverage and innovation-driven momentum position it for sustained adoption despite rising competition.
Solventum ( SOLV ) Upgraded to Strong Buy: What Does It Mean for the Stock?
Solventum (SOLV) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SOLV or DHR: Which Is the Better Value Stock Right Now?
SOLV vs. DHR: Which Stock Is the Better Value Option?
Global Wound Dressings Market Set to Reach USD 15.87 Billion by 2030 | MarketsandMarkets™
Delray Beach, FL, Nov. 10, 2025 ( GLOBE NEWSWIRE ) -- The global wound dressings market, valued at US$10.95 billion in 2024, stood at US$11.60 billion in 2025 and is projected to advance at a resilient CAGR of 6.5% from 2025 to 2030, culminating in a forecasted valuation of US$15.87 billion by ...
Solventum ( SOLV ) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool.Thursday, November 6, 2025 at 4:30 p.m. ETNeed a quote from a Motley Fool analyst? Email [email protected] reading ...
SOLV Gains on Q3 Earnings & Sales Beat, Raises '25 EPS Outlook
Solventum posts strong Q3 results with a revenue and earnings beat, lifts 2025 EPS guidance on solid MedSurg and HIS growth.
Solventum ( SOLV ) Surpasses Q3 Earnings and Revenue Estimates
Solventum (SOLV) delivered earnings and revenue surprises of +4.90% and +0.33%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
XRAY Stock Declines on Q3 Earnings Miss & Lower 2025 EPS View
DENTSPLY SIRONA shares drop as Q3 earnings miss estimates and 2025 EPS guidance is cut amid segment weakness.
Avanos Medical Gains on Q3 Earnings Beat, Raises '25 Sales View
Avanos Medical posts a Q3 earnings and sales beat, boosts 2025 outlook as Specialty Nutrition drives solid double-digit growth.
MCK Q2 Earnings Beat, Sales Miss, '26 EPS View Up, Stock Down
McKesson posts a strong Q2 earnings beat but a slight sales miss, lifts its 2026 EPS outlook on solid specialty and tech segment growth.
Rigetti Computing to Post Q3 Earnings: What's in Store for the Stock?
RGTI's Q3 results are likely to gain from U.S. funding clarity, new contracts and gains from its next-gen quantum system.
CLOV Q3 Earnings Miss, Stock Falls on Raised Insurance BER View
Clover Health's Q3 sales soar 50%, but higher Insurance costs and a raised BER outlook weigh on investor sentiment.
COR Q4 Earnings & Revenues Beat Estimates, Gross Margin Improves
Cencora's Q4 results top estimates with 15% EPS growth and stronger margins, as GLP-1 demand and the RCA acquisition fuel solid segment gains.
FMS Stock Rises as Q3 Earnings Beat Estimates, Revenues Gain Y/Y
Fresenius Medical Care's Q3 earnings and revenues beat estimates, fueled by margin gains and solid organic growth across segments.
Unveiling Solventum ( SOLV ) Q3 Outlook: Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of Solventum (SOLV) for the quarter ended September 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
DENTSPLY SIRONA to Post Q3 Earnings: What's in Store for the Stock?
Dentsply Sirona's Q3 results may reveal ongoing softness in U.S. demand and orthodontic segments despite steady cost control.
Solventum to Post Q3 Earnings: Is a Beat Likely for the Stock?
Solventum's Q3 results may reflect softer sales and tariff impacts, though pricing discipline and core growth drivers likely aided margins.
Will Strong Segmental Performance Drive MCK's Top Line in Q2?
McKesson's Q2 results may show steadier growth as strong U.S. pharmaceutical and RxTS momentum drive its expanding top line.
Up 30% This Year and With Plenty of Room to Run, This Blue Chip Stock Is a Value Investor's Dream
End markets aren't helping much, yet, but this industrial company's operational improvements are making waves among investors.
DexCom Stock Falls Despite Q3 Earnings Beat, 2025 Revenue View Raised
DXCM posts double-digit Q3 growth and raises 2025 revenue outlook, but shares tumble despite strong CGM momentum and innovation updates.
SYK Stock Falls Despite Q3 Earnings & Sales Beat, '25 View Up
Stryker's Q3 results top estimates with double-digit sales and profit growth, but shares slip as investors weigh tariff pressures despite an upbeat 2025 outlook.
Avantor Stock Plunges as Q3 Earnings Miss Estimates, Revenues Down Y/Y
AVTR's Q3 earnings and revenue fell short of estimates, leading the company to cut its full-year 2025 outlook.
DaVita Stock Down Post Q3 Earnings Miss Estimates, Revenues Up Y/Y
DVA's Q3 earnings miss estimates despite revenue growth, as margins tightened and shares slipped post-results.
TMDX Stock Falls Despite Q3 Earnings Beat Estimates, Revenues Up Y/Y
TransMedics posts surging profit and higher revenues on strong OCS and logistics growth, yet its shares slide despite upbeat Q3 results.
OPK Q3 Earnings Beat Estimates, Sales Miss, Gross Margin Expands
OPKO Health's Q3 earnings top estimates despite lower sales. Cost cuts and product strength boost margins and operating income.
GKOS Stock Surges Following Q3 Earnings & Revenue Beat, Guidance Raised
Glaukos reported a narrower Q3 loss, strong 38% sales jump, and raised 2025 outlook as iDose TR and Epioxa fuel momentum across key franchises.
BAX Stock Falls Following Q3 Earnings Beat & Sales Miss, '25 EPS View Down
Baxter's Q3 earnings top forecasts, but sales lag and 2025 EPS guidance slips. shares fall despite strength in Pharma and Advanced Surgery.
CAH Q1 Earnings Beat Estimates, '26 EPS View Up, Stock Gains
Cardinal Health delivered a strong Q1 beat and lifted its 2026 EPS outlook, fueled by broad-based growth and rising profits across all business segments.
Solventum ( SOLV ) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Solventum (SOLV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GE HealthCare Q3 Earnings and Revenues Beat Estimates, Net Margin Falls
GE HealthCare's Q3 results show steady revenue growth as strong imaging and diagnostics offset tariff and margin pressures.
Will Solventum ( SOLV ) Beat Estimates Again in Its Next Earnings Report?
Solventum (SOLV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
RVTY Q3 Earnings Beat, Sales In Line, '25 EPS View Raised
Revvity beats on Q3 earnings and raises 2025 EPS view, as balanced segment performance offsets margin pressure.
Does GEHC Stock Deserve a Spot in Your Portfolio Ahead of Q3 Earnings?
GE HealthCare's Q3 results are expected to show steady growth from Imaging and Diagnostics, though tariffs may weigh on margins and EPS.
Unpacking the Latest Options Trading Trends in 3M - 3M ( NYSE:MMM )
Investors with a lot of money to spend have taken a bullish stance on 3M ( NYSE:MMM ) . We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
SOLV or MEDP: Which Is the Better Value Stock Right Now?
SOLV vs. MEDP: Which Stock Is the Better Value Option?
TMO to Report Q3 Earnings: Life Science Solutions Segment in Focus
Thermo Fisher's Q3 results on Oct. 22 are set to spotlight gains from new launches and acquisitions across key growth segments.
GEHC Stock Up Following New Launch to Streamline Perinatal Workflow
GE HealthCare unveils CareIntellect for Perinatal, a SaaS tool aimed at improving maternal and fetal care delivery.
BD Stock Down Despite Making Progress in the Treatment of PAD Lesions
BDX advances PAD care with first patient enrolled in the XTRACT Registry using its dual-action Rotarex system.
BD Stock Down Despite Tie-Up to Boost Single-Cell Sequencing Workflow
BDX teams with Opentrons to automate single-cell sequencing, advancing its multiomics and biosciences strategy.
PacBio Stock Dips Despite Announcing Expanded Partnership With seqWell
PACB expands seqWell partnership to enhance its sequencing workflow offerings with a new multiplexing kit.
SOLV vs. MEDP: Which Stock Is the Better Value Option?
Investors with an interest in Medical Services stocks have likely encountered both Solventum ( SOLV Quick QuoteSOLV - ) and Medpace ( MEDP Quick QuoteMEDP - ) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
Labcorp Holdings Inc. ( LH ) Hit a 52 Week High, Can the Run Continue?
Labcorp (LH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Baxter Stock Slips Despite Latest Launch to Boost Patient Monitoring
BAX launches FDA-cleared Connex 360 monitor, aiming to boost frontline care and streamline patient monitoring.
SOLV or MEDP: Which Is the Better Value Stock Right Now?
SOLV vs. MEDP: Which Stock Is the Better Value Option?
Is Solventum Corporation ( SOLV ) Stock Outpacing Its Medical Peers This Year?
Here is how Solventum (SOLV) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.
SOLV Strong Q2 Results Signal Momentum: Is the Stock Worth Buying Now?
Solventum beats on Q2 earnings, raises guidance, and powers ahead with transformation despite looming tariff headwinds.
